NZ launches world-first bird flu vaccination for endangered kākāpō as virus arrives

New Zealand's Department of Conservation moved to vaccinate ninety endangered kākāpō this week as a seabird washed up on Wellington's Petone Beach tested positive for avian influenza—marking the moment the virus arrived on the country's shores. The vaccination campaign represents something the world has not attempted before: a preemptive immunization of critically endangered birds against a pathogen that had not yet reached them. It is a gamble born of necessity, and it arrives at a moment of unexpected hope for a species that has hovered at the edge of extinction for decades.

The Department of Conservation had been preparing for this scenario for over a year. After a successful vaccine trial concluded, officials began inoculating core breeding populations of five species—kākāpō, takahe, kakī, tuturuata, and kākāriki karaka—as the virus swept through Australia. Lydia Udstrom, the DOC veterinarian overseeing the kākāpō programme, explained the logic in stark terms: this was a world first, an attempt to shield the birds before the threat materialized. The timing proved fortuitous. Whenua Hou, the island where most of the vaccinated kākāpō live, sits in a zone of heavy overlap with petrels and seabirds—the very species most likely to carry the virus across vast distances. When those migratory birds departed for their seasonal travels, the island fell quiet, creating an ideal window to vaccinate the resident population before the travelers returned, potentially sick.

The vaccination strategy reveals the intricate calculus of modern conservation. Of roughly seventy kākāpō expected to remain long-term on Whenua Hou, most would receive the two-dose regimen spaced three to five weeks apart. But not all. The Department deliberately left some birds unvaccinated, treating them as a control group. If those unvaccinated birds encountered the virus naturally and survived, blood samples would confirm their exposure and immunity—crucial data for understanding how the disease might move through a wild population. There was an acknowledgment, too, of a darker possibility: one of the unvaccinated birds might sicken and die. It would be devastating, but the knowledge gained would matter for a species that must ultimately survive in the wild, doing wild things, beyond the reach of human protection.

The timing of this vaccination campaign coincides with an extraordinary moment in kākāpō recovery. This breeding season has shattered all records. Ninety chicks have hatched—a number that took sixteen years to accumulate under the old recovery trajectory. One chick has already reached the 150-day milestone, eligible to be counted in the official population tally, which would rise to 236 birds, the first increase in four years. The stakes of protecting these birds have never been higher. Louise Porter, a DOC ranger, underscored the magnitude: in a single breeding season, the programme had produced as many chicks as it had in its first sixteen years of operation. That acceleration makes the arrival of bird flu feel like a test of whether conservation gains can hold against a new threat.

The vaccination itself is straightforward in principle. The first injection primes the immune system to produce antibodies. The second, administered weeks later, generates higher and more durable antibody levels. Eight birds from the original vaccine trial remain on Whenua Hou, now two years past their initial vaccination. Giving them a booster now will allow researchers to measure how quickly their immune systems respond—a window into the durability of protection. The Department anticipates a severe first wave of infection, followed by a gradual shift toward endemic status, as the virus becomes woven into the landscape. The vaccination programme is designed to shepherd the critical breeding populations through that initial onslaught, buying time for the birds to develop natural immunity to a pathogen that, once established, will never leave.

The vaccination effort has also surfaced a tension in New Zealand's broader approach to bird flu. Melvin Pike, who raises about two hundred birds in Wairarapa, has called for vaccination access to extend beyond native species to rare poultry breeds. The concern is straightforward: losses among rare poultry would be catastrophic, given how few breeders exist for those lines. But the Ministry for Primary Industries has resisted, citing trade complications. If vaccination were permitted in commercial poultry, some trading partners would close their markets to New Zealand goods unless countries agreed to accept imports from vaccinated flocks. There is also the practical matter that broiler chickens do not live long enough for immunity to fully develop before slaughter. And vaccinated birds can mask the virus, making it harder to distinguish them from infected ones using standard diagnostic tests. For now, the vaccination shield remains reserved for the wild and the endangered, a resource allocated to the species most at risk of vanishing entirely.